Life Science Today
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs.
Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
The Niche Episode 046 – Vertex, CRISPR, Versant, GSK, Syneos + Medable, Velocity
Billion-dollar amendments, billion-dollar funds, GSK gets oncology nod from FDA, and two stories in clinical research.
Sponsors
https://www.thescopemethod.com
Story References
https://tinyurl.com/Niche-046-1
https://tinyurl.com/Niche-046-2
https://tinyurl.com/Niche-046-3
https://tinyurl.com/Niche-046-4
https://tinyurl.com/Niche-046-5
Music by Luke Goodson
https://www.soundcloud.com/lukegoodson
The Niche Podcast brings you interviews with industry experts and top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.
The Niche Episode 045 – ThermoFisher + PPD, Trodelvy 2x, DiaSorin + Luminex, Merck, Novartis, and Vicarious
Massive acquisitions in the CRO space, Trodelvy 2x, diagnostic acquisitions, Merck closes COVID vaccine program, Xolair get’s self-injection nod, and tiny robots go for massive SPAC.
Sponsors
https://www.thescopemethod.com
Story References
https://tinyurl.com/Niche-045-1
https://tinyurl.com/Niche-045-2
https://tinyurl.com/Niche-045-3
https://tinyurl.com/Niche-045-4
https://tinyurl.com/Niche-045-5
https://tinyurl.com/Niche-045-6
Music by Luke Goodson
https://www.soundcloud.com/lukegoodson
The Niche Podcast brings you interviews with industry experts top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.
The Niche Episode 044 – Gilead, Bio-Techne + Asuragen, Vysioneer, Achilles
Gilead gets FDA approval in oncology, Bio-Techne acquires Asuragen, AI for tumor targeting, and Achilles completes $175M IPO.
Sponsors
https://www.thescopemethod.com
Story References
https://tinyurl.com/Niche-044-1
https://tinyurl.com/Niche-044-2
https://tinyurl.com/Niche-044-3
https://tinyurl.com/Niche-044-4
Music by Luke Goodson
https://www.soundcloud.com/lukegoodson
The Niche Podcast brings you interviews with industry experts top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.
The Niche Episode 043 – Charles River, IQVIA, Agios, Alloy
Charles River acquires Retrogenix, IQVIA fully acquires Q2 Solutions, Agios sells $1.8B in oncology, and Alloy forges a $75M series C.
Sponsors
https://www.thescopemethod.com
Story References
https://tinyurl.com/Niche-043-1
https://tinyurl.com/Niche-043-2
https://tinyurl.com/Niche-043-3
https://tinyurl.com/Niche-043-4
https://tinyurl.com/Niche-043-5
Music by Luke Goodson
https://www.soundcloud.com/lukegoodson
The Niche Podcast brings you interviews with industry experts top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.
The Niche Episode 042 – Interview with Dr. Benjamin Schwartz on Digital Healthcare (Bonus)
This is our March bonus episode. I sit down with Dr. Benjamin Schwartz an orthopedic surgeon and digital health expert. We talk digital integration, healthcare cost, and how you can get involved in the space.
Sponsors
https://www.thescopemethod.com
Guest References
https://www.benschwartzmd.com/
https://www.linkedin.com/in/ben-schwartz-md/
Music by Luke Goodson
https://www.soundcloud.com/lukegoodson
The Niche Podcast brings you interviews with industry experts top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.
The Niche Episode 041 – NeoGenomics + Trapelo, Medtronic, Gyroscope, Design
Mergers in precision oncology testing, Medtronic breakthrough valve replacement, Gyroscope raises capital for AMD, and small molecule genetic treatments get $240M IPO.
Sponsors
https://www.thescopemethod.com
Story References
https://tinyurl.com/Niche-041-1
https://tinyurl.com/Niche-041-2
https://tinyurl.com/Niche-041-3
https://tinyurl.com/Niche-041-4
Music by Luke Goodson
https://www.soundcloud.com/lukegoodson
The Niche Podcast brings you interviews with industry experts top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.
Responses